|Day Low/High||6.79 / 6.96|
|52 Wk Low/High||3.32 / 12.90|
Here's how to potentially rake in some fat profits off a number of hot breakout setups.
Positive results from the GENUINE Phase 3 study to be featured in an oral presentation
The most recent short interest data has been released for the 03/31/2017 settlement date, which shows a 1,802,705 share increase in total short interest for TG Therapeutics Inc , to 10,443,471, an increase of 20.86% since 03/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Jim Cramer is bullish on Twilio, HubSpot and Cemex; he's bearish on Suburban Propane Partners.
No, people aren't suddenly deciding they want to go back to shopping at the mall, says Jim Cramer.
First-in-human trial expected to launch in 2017
Investors eyeing a purchase of TG Therapeutics Inc shares, but cautious about paying the going market price of $11.43/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $10 strike, which has a bid at the time of this writing of $1.15.
Presentation Scheduled for Tuesday, March 21, 2017 at 3:20pm ET
Presentation Scheduled for Tuesday, March 14, 2017 at 3:00pm PT
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Investor Conference Call to be held Friday, March 10, 2017 at 8:30am ET
Nine biotech and drug companies want FDA approval, but need changed standards to get it.
Jim Cramer is bullish on Arconic, Treehouse Foods, Magellan Midstream Partners.
Jim Cramer says if Trump really wants to lower drug prices, he should target our trading partners.
These stocks are showing short-term gain catalysts and longer-term growth potential. Here's how to trade them.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in TG Therapeutics Inc , where a total volume of 3,146 contracts has been traded thus far today, a contract volume which is representative of approximately 314,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 78.1% of TGTX's average daily trading volume over the past month, of 403,030 shares.
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of TG Therapeutics, Inc.
Single agent TG-1101 treatment resulted in 45% ORR in NHL and CLL patients previously exposed to rituximab, with a 31% ORR observed in rituximab-refractory patients
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased TG Therapeutics, Inc.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.